Autopsy report · NCT04409327

Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

“Insufficient accrual rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 6 months before it stopped.
• 36 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Restorbio Inc.

Sponsor type

Industry

Conditions

COVID19

Interventions

RTB101; Placebo

Participants

36

Sites

1

Countries

United States

Trials that died the same way

• Osteoarthritis Shoulder Injection Study
  “insufficient rate of accrual” (98% match in meaning)
• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (89% match in meaning)
• A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
  “Poor accrual rate” (86% match in meaning)
• Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Treatment-Resistant Keratitis
  “Low accrual rate” (85% match in meaning)
• Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
  “Insufficient accrual” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.